Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome

Fertility and Sterility

Volumn 77, Issue 2, 2002, Pages 209-215

  Nestler, John E ^a   Stovall, Dale ^a   Akhter, Nausheen ^b   Iuorno, Maria J ^a   Jakubowicz, Daniela J ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Hospital de Clinicas Caracas   (Venezuela)

Author keywords

Clomiphene; Infertility; Inositol; Metformin; Ovulation; Polycystic ovary syndrome; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CLOMIFENE; GONADOTROPIN; INOSITOL; INSULIN SENSITIZING AGENT; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

ALGORITHM; FEMALE; FEMALE FERTILITY; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER TOXICITY; OUTCOMES RESEARCH; OVARY POLYCYSTIC DISEASE; OVULATION; OVULATION INDUCTION; PATHOPHYSIOLOGY; PREGNANCY RATE; PRIORITY JOURNAL; REVIEW;

ALGORITHMS; CLOMIPHENE; FEMALE; FERTILITY AGENTS, FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFERTILITY, FEMALE; INSULIN RESISTANCE; METFORMIN; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY;

EID: 0036153118     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(01)02963-6     Document Type: Review

References (59)

1. Insulin resistance in nonobese patients with polycystic ovarian disease
2. Characterization of groups of hyperandrogenemic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia
3. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome
4. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome
5. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome
6. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome
7. A twin study of polycystic ovary syndrome
8. Consensus Development Conference on Insulin Resistance. November 5-6, 1997. American Diabetes Association
9. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome
10. Impact of obesity on insulin action in volunteers with normal glucose tolerance; demonstration of a threshold for the adverse effect of obesity
11. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens
12. Clinical and laboratory predictors of clomiphene response
13. Relationship of weight to successful induction of ovulation with clomiphene citrate
14. Weight control and its beneficial effect on fertility in women with obesity and polycystic ovary syndrome
15. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome; role of insulin sensitivity and luteinizing hormone
16. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
17. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome
18. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome
19. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome
20. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome
21. Administration of metformin to a diabetic woman with extreme hyperandrogenemia of nontumoral origin; management of infertility and prevention of inadvertent masculinization of a female fetus
22. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche
23. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome
24. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome; a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
25. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome
26. Association of metformin and pregnancy in the polycystic ovary syndrome. A report of three cases
27. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone
28. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women
29. Can metformin reduce insulin resistance in polycystic ovary syndrome?
30. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome
31. Efficacy of metformin in type II diabetes; results of a double-blind, placebo-controlled, dose-response trial
32. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome; a multicenter, double blind, placebo-controlled trial
33. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome
34. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
35. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome
36. High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome
37. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
38. Insulin sensitizers and polycystic ovary syndrome; can a diabetes medication treat infertility?
39. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome
40. Metformin treatment of patients with polycystic ovarian syndrome undergoing IVF increases the number of mature oocytes, the fertilization rate and the number of embryos with changes in the levels of insulin-like growth factors
41. Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin
42. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome
43. Hypersecretion of luteinising hormone, infertility, and miscarriage
44. Recurrent early miscarriage and polycystic ovaries
45. Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage
46. Subfertility and risk of spontaneous abortion
47. Influence of past reproductive performance on risk of spontaneous abortion
48. An informative protocol for the investigation of recurrent miscarriage; preliminary experience of 500 consecutive cases
49. Recurrent miscarriage; screening for polycystic ovaries and subsequent pregnancy outcome
50. Obesity is a risk factor for early pregnancy loss after IVF or ICSI
51. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome
52. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion; a pilot study
53. Metformin in management of pregnant insulin-independent diabetics
54. Oral hypoglycaemics in the first trimester and fetal outcome
55. The management of non-insulin-dependent diabetes during pregnancy
56. Troglitazone inhibits progesterone production in porcine granulosa cells
57. Polycystic ovary syndrome; a disorder for the generalist